Staphylococcus aureus Bacteremia and Endocarditis. Francis P. Tally, M.D. Senior Vice President and Chief Scientific Officer Cubist Pharmaceuticals, Inc . Summary: Staphylococcus aureus Bacteremia. Significant unmet medical need
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Francis P. Tally, M.D.
Senior Vice President and Chief Scientific Officer
Cubist Pharmaceuticals, Inc.
Proportion of BSI*
S. aureus **
* Total 20,978 monomicrobial bacteremias
** 41% resistant to Methicillin
Wisplinghoff et al. CID 29:309-317, 2004
Case Fatality = 82%
Number of patients
Skinner & Keefer. Arch Int. Med 68:851-75, 1941
Cosgrove SE et al. Clin Infect Dis 36:53-59, 2003
EFFICACY IN MSSA/MRSA
MIC = Minimum Inhibitory Concentration
Source: Sakoulas et al.JCM, June 2004